Acute Lymphoblastic Leukemia

FDA Grants Iclusig® Expanded Approval for CML (December 14, 2016)

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive... Continue Reading

Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia (September 26, 2016)

Acccording to results recently published in the New England Journal of Medicine, young adults with CD20-positive, Philadelphia chromosome  (PH)-negative acute lymphoblastic leukemia (ALL), experience... Continue Reading

Inotuzumab Ozogamicin Improves Progression-Free Survival in Acute Leukemia (September 6, 2016)

The investigative agent, inotuzumab ozogamicin, significantly improves progression-free survival and 2-year survival rates among patients with acute lymphoblastic leukemia that has stopped responding to... Continue Reading

Pass It On: July is National Leukemia and Lymphoma Awareness Month (September 1, 2016)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia... Continue Reading

Blincyto® Improves Survival in Type of Acute Lymphoblastic Leukemia (June 23, 2016)

The immunotherapeutic agent, Blincyto (blinatumomab), improves survival compared to standard therapy among patients with B-cell precursor, Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia... Continue Reading

Hydrocortisone Significantly Improves Neuropsychological Issues in Some Children with Leukemia (May 16, 2016)

The use of physiologic doses of hydrocortisone appears to significantly improve neuropsychological issues caused by treatment including dexamethasone among children with acute lymphoblastic leukemia. These... Continue Reading

Blincyto® is Promising New Treatment Option for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (January 19, 2016)

Amgen, a biotechnology company, has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic... Continue Reading

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings (December 31, 2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented... Continue Reading

Addition of Rituxan Improves Outcomes in Some Acute Lymphoblastic Leukemias (December 16, 2015)

The addition of Rituxan (rituximab) to standard chemotherapy-based regimens improves outcomes among patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) that is CD20-positive. These results... Continue Reading

Midostaurin Improves Survival in Subset of Acute Myeloid Leukemia (December 15, 2015)

The targeted agent, midostaurin, has demonstrated a survival improvement among patients with acute myeloid leukemia (AML) that has the TMS-like tyrosine kinase 3 (FLT3) mutation. These results were presented... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

Blincyto® in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Appears Promising (July 23, 2015)

Biotechnology company Amgen has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic... Continue Reading

Intravenous Administration of Erwinaze® Approved by FDA (February 18, 2015)

CancerConnect News: The U.S. Food and Drug Administration (FDA) recently approved the intravenous administration of Erwinaze® (asparaginase Erwinia chrysanthemi).  Erwinaze is utilized as a component... Continue Reading

FDA Approves Blinatumomab for Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia (January 12, 2015)

On December 3, 2014, the U. S. Food and Drug Administration granted accelerated approval for BLINCYTOTM (blinatumomab) for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell... Continue Reading

CD19-Directed CAR T Cells Effective in Management of Relapsed/Refractory Acute Lymphoblastic Leukemia (October 27, 2014)

In a study recently published in The New England Journal of Medicine, doctors have reported achieving sustained remissions in children and adults with relapsed/refractory acute lymphoblastic leukemia (ALL)... Continue Reading

Amgen’s BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia (October 10, 2014)

THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood... Continue Reading

Iclusig Approved for CML and ALL (January 4, 2013)

The U.S. Food and Drug Administration (FDA) has approved Iclusig™ (ponatinib) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS